{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:03:09Z","timestamp":1792202589734,"version":"4.4.0"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.biopha.2025.118911","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:34:21Z","timestamp":1767681261000},"page":"118911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Revolutionizing uveitis treatment with nanotechnology: Innovations, barriers, and strategic solutions"],"prefix":"10.1016","volume":"194","author":[{"given":"MohammadKarim","family":"Johari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roghayyeh","family":"Baghban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheleh","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.iio.0000155938.83083.94","article-title":"Epidemiology of uveitis","volume":"45","author":"Wakefield","year":"2005","journal-title":"Int. Ophthalmol. Clin."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41433-024-03519-x","article-title":"The history of uveitis: from antiquity to the present day","volume":"39","author":"Ghadiri","year":"2025","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2025.118911_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2024.1412930","article-title":"Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond","volume":"4","author":"Chauhan","year":"2024","journal-title":"Front. Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.18502\/jovr.v17i2.10804","article-title":"A review of systemic biologics and local immunosuppressive medications in uveitis","volume":"17","author":"N","year":"2022","journal-title":"J. Ophthalmic Vis. Res"},{"issue":"12","key":"10.1016\/j.biopha.2025.118911_bib5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jamaophthalmol.2019.3964","article-title":"Antimetabolite therapy for uveitis: methotrexate or mycophenolate?","volume":"137","author":"Jabs","year":"2019","journal-title":"JAMA Ophthalmol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118911_bib6","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ophtha.2013.08.029","article-title":"The future of uveitis treatment","volume":"121","author":"Lin","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118911_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/1744666X.2020.1798230","article-title":"The current status of biological treatment for uveitis","volume":"16","author":"Gaggiano","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118911_bib9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/imj.14215","article-title":"The use of biologic agents in the management of uveitis","volume":"49","author":"Trivedi","year":"2019","journal-title":"Intern. Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J. Ophthalmic Inflamm. Infect."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/jop.2021.0098","article-title":"Current knowledge of biologics in treatment of noninfectious uveitis","volume":"38","author":"Gupta","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2025.118911_bib12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/pharmaceutics13081224","article-title":"A review of ocular drug delivery platforms and drugs for infectious and noninfectious uveitis: the past, present, and future","volume":"13","author":"Conrady","year":"2021","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.biopha.2025.118911_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3109\/02713683.2010.508867","article-title":"In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug delivery on rabbit eye","volume":"35","author":"Rafie","year":"2010","journal-title":"Curr. Eye Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib14","first-page":"42","article-title":"Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior and posterior segments of the eye","volume":"10","author":"Velagaleti","year":"2010","journal-title":"Drug Deliv. Technol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118911_bib15","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1167\/iovs.11-8178","article-title":"Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema","volume":"52","author":"Tanito","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118911_bib16","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1021\/mp500332m","article-title":"On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein","volume":"11","author":"Mun","year":"2014","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/jop.2006.22.465","article-title":"Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits","volume":"22","author":"Gunda","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"04","key":"10.1016\/j.biopha.2025.118911_bib18","first-page":"201","article-title":"Recent advances in nanoparticle-based drug delivery systems","volume":"1","author":"Maurya","year":"2024","journal-title":"J. Drug Discov. Health Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12195-022-00727-x","article-title":"High-density branched PEGylation for nanoparticle drug delivery","volume":"15","author":"Cahn","year":"2022","journal-title":"Cell. Mol. Bioeng."},{"issue":"7","key":"10.1016\/j.biopha.2025.118911_bib20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3390\/pharmaceutics16070852","article-title":"Carrier systems for advanced drug delivery: improving drug solubility\/bioavailability and administration routes","volume":"16","author":"Losada-Barreiro","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.biopha.2025.118911_bib21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/biomedicines10092055","article-title":"Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics","volume":"10","author":"Bhalani","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s13204-021-01744-4","article-title":"Tacrolimus-loaded chitosan-coated nanostructured lipid carriers: preparation, optimization and physicochemical characterization","volume":"11","author":"Dasineh","year":"2021","journal-title":"Appl. Nanosci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118911_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/21691401.2016.1243545","article-title":"Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation","volume":"45","author":"Pandit","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/pharmaceutics14010090","article-title":"Lipid nanoparticles for the posterior eye segment","volume":"14","author":"Bonilla","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.biopha.2025.118911_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1139\/cjc-2017-0193","article-title":"Dendrimers for ocular drug delivery","volume":"95","author":"Lancina","year":"2017","journal-title":"Can. J. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2025.118911_bib26","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/pharmaceutics13101637","article-title":"A systematic review of drug-loaded electrospun nanofiber-based ophthalmic inserts","volume":"13","author":"Omer","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejpb.2012.12.010","article-title":"Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies","volume":"84","author":"Sabzevari","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/biomedicines9040396","article-title":"Superoxide Dismutase 1 Nanoparticles (Nano-SOD1) as a potential drug for the treatment of inflammatory eye diseases","volume":"9","author":"Vaneev","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118911_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2019.01.018","article-title":"Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis","volume":"296","author":"Luo","year":"2019","journal-title":"J. Control. Release"},{"issue":"35","key":"10.1016\/j.biopha.2025.118911_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb7878","article-title":"Systemic anti-inflammatory therapy aided by double-headed nanoparticles in a canine model of acute intraocular inflammation","volume":"6","author":"Ganugula","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/107555303321223035","article-title":"Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa)","volume":"9","author":"Chainani-Wu","year":"2003","journal-title":"J. Altern. Complement. Med."},{"key":"10.1016\/j.biopha.2025.118911_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00745-9","article-title":"Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy","volume":"19","author":"Swetledge","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Group SoUNW","year":"2005","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcjo.2024.07.013","article-title":"Anterior uveitis for the comprehensive ophthalmologist","volume":"60","author":"Xie","year":"2025","journal-title":"Can. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib35","first-page":"14","article-title":"Anterior segment examination with slit-lamp biomicroscope: what should be highlighted?","volume":"3","author":"Sakti","year":"2021","journal-title":"Eur. J. Med. Health Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib36","first-page":"375","article-title":"Review of Intermediate Uveitis","volume":"2","author":"Lai","year":"2013","journal-title":"AsiaPac. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118911_bib37","series-title":"Encyclopedia of Infection and Immunity","first-page":"219","article-title":"Viral Ocular Infections","author":"Cabrera-Aguas","year":"2022"},{"issue":"null","key":"10.1016\/j.biopha.2025.118911_bib38","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/OPTH.S89428","article-title":"Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA","volume":"9","author":"Engelhard","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118911_bib39","doi-asserted-by":"crossref","unstructured":"Dunn J.P. Uveitis. Primary Care: Clinics in Office Practice. 2015;42(3):305-323.","DOI":"10.1016\/j.pop.2015.05.003"},{"key":"10.1016\/j.biopha.2025.118911_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114869","article-title":"Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis","volume":"198","author":"Teabagy","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2005.12.012","article-title":"Anti-TNF therapies in the management of acute and chronic uveitis","volume":"33","author":"Hale","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2025.118911_bib42","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Fern\u00e1ndez S., Mart\u00edn-Mola E. Uveitis. Best Practice & Research Clinical Rheumatology. 2006;20(3):487-505.","DOI":"10.1016\/j.berh.2006.03.008"},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118911_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.695904","article-title":"Epidemiology and risk factors in non-infectious uveitis: a systematic review","volume":"8","author":"Joltikov","year":"2021","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41433-018-0224-y","article-title":"Infectious uveitis: an Asian perspective","volume":"33","author":"Agarwal","year":"2019","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib47","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","article-title":"Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"123","author":"Dick","year":"2016","journal-title":"Ophthalmology"},{"issue":"7234","key":"10.1016\/j.biopha.2025.118911_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bmj.320.7234.555","article-title":"Management of chronic uveitis","volume":"320","author":"McCluskey","year":"2000","journal-title":"Bmj"},{"issue":"null","key":"10.1016\/j.biopha.2025.118911_bib49","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2147\/OPTH.S90153","article-title":"Traumatic uveitis in the mid-Atlantic United States","volume":"9","author":"Engelhard","year":"2015","journal-title":"Clin. Ophthalmol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118911_bib50","doi-asserted-by":"crossref","DOI":"10.21037\/apm-21-3549","article-title":"Analysis of the clinical diagnosis and treatment of uveitis","volume":"10","author":"Wang","year":"2021","journal-title":"Ann. Palliat. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118911_bib51","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of macular edema on visual acuity in uveitis","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2025.118911_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2018.02.019","article-title":"Autoimmunity, autoinflammation, and infection in uveitis","volume":"189","author":"Forrester","year":"2018","journal-title":"Am. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118911_bib53","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.autrev.2010.05.017","article-title":"Current therapeutic approaches to autoimmune chronic uveitis in children","volume":"9","author":"Simonini","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2025.118911_bib54","series-title":"Ocular inflammatory disease and uveitis manual: Diagnosis and treatment","author":"Huang","year":"2012"},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10238-015-0345-6","article-title":"Autoimmune uveitis: clinical, pathogenetic, and therapeutic features","volume":"16","author":"Prete","year":"2016","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40123-014-0023-x","article-title":"Review of systemic immunosuppression for autoimmune uveitis","volume":"3","author":"Castiblanco","year":"2014","journal-title":"Ophthalmol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2025.118911_bib57","first-page":"475","article-title":"Evidence-based treatment for uveitis","volume":"21","author":"Gamalero","year":"2019","journal-title":"Isr. J. Med. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118911_bib58","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib59","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/jfb6030650","article-title":"Intraocular Implants for the Treatment of Autoimmune Uveitis","volume":"6","author":"Lee","year":"2015","journal-title":"J. Funct. Biomater."},{"issue":"7","key":"10.1016\/j.biopha.2025.118911_bib60","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41433-022-02121-3","article-title":"Paediatric anterior uveitis management in the USA: a single-centre, 10-year retrospective chart review exploring the efficacy and safety of systemic immunomodulatory therapy","volume":"37","author":"Huynh","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2025.118911_bib61","first-page":"467","article-title":"Roles of drug transporters in blood-retinal barrier","author":"Liu","year":"2019","journal-title":"Drug Transp. Drug Dispos. Eff. Toxic."},{"key":"10.1016\/j.biopha.2025.118911_bib62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fimmu.2012.00296","article-title":"The privileged immunity of immune privileged organs: the case of the eye","volume":"3","author":"Benhar","year":"2012","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12348-019-0184-9","article-title":"The broad spectrum of application of optical coherence tomography angiography to the anterior segment of the eye in inflammatory conditions: a review of the literature","volume":"9","author":"Pichi","year":"2019","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.biopha.2025.118911_bib64","series-title":"Precision Health in the Digital Age: Harnessing AI for Personalized Care","first-page":"209","article-title":"The clinical impact and transformative potential of artificial intelligence in ophthalmology","author":"Charonis","year":"2025"},{"key":"10.1016\/j.biopha.2025.118911_bib65","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.2147\/OPTH.S495307","article-title":"Artificial intelligence in uveitis: Innovations in diagnosis and therapeutic strategies","author":"Murugan","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118911_bib66","unstructured":"Malik T.G., Ain N.U. Perspective Chapter: Challenges in Managing Uveitis in Low-to Middle-Income Countries. 2025."},{"issue":"10","key":"10.1016\/j.biopha.2025.118911_bib67","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/02713683.2024.2355659","article-title":"Cost-effectiveness analysis of adalimumab versus cyclosporine for vogt-koyanagi-harada disease: a randomized controlled study","volume":"49","author":"Dai","year":"2024","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.biopha.2025.118911_bib68","first-page":"1","article-title":"Economic burden and cost-effectiveness of management of non-infectious uveitis: a systematic review","author":"Sriranganathan","year":"2025","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/09273948.2024.2344712","article-title":"Adalimumab for the treatment of non-infectious uveitis: a real life experience","volume":"33","author":"Raad","year":"2025","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.biopha.2025.118911_bib70","series-title":"The quality of life of patients with eye diseases","author":"Yu","year":"2022"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10792-025-03413-9","article-title":"Precision medicine in uveitis: redefining treatment optimization through biomarkers and tailored therapies","volume":"45","author":"Neri","year":"2025","journal-title":"Int. Ophthalmol."},{"issue":"46","key":"10.1016\/j.biopha.2025.118911_bib72","doi-asserted-by":"crossref","first-page":"27835","DOI":"10.1039\/D0RA04971A","article-title":"Nanocarriers for ocular drug delivery: current status and translational opportunity","volume":"10","author":"Gorantla","year":"2020","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib73","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10792-024-03000-4","article-title":"Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives","volume":"44","author":"Nirbhavane","year":"2024","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118911_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123704","article-title":"Engineering a novel water-in-oil biocompatible microemulsion system for the ocular delivery of dexamethasone sodium phosphate in the treatment of acute uveitis","volume":"650","author":"Abd-Elaty","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118911_bib75","article-title":"Prednisolone loaded-cationic nanoemulsion formulation for uveitis management","volume":"92","author":"Attia","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12951-024-02402-x","article-title":"OCTN2-and ATB0,+-targeted nanoemulsions for improving ocular drug delivery","volume":"22","author":"Tang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biopha.2025.118911_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-02857-1","article-title":"Preparation and evaluation of cubosomes\/cubosomal gels for ocular delivery of beclomethasone dipropionate for management of uveitis","volume":"37","author":"Gaballa","year":"2020","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib78","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/10837450.2019.1578370","article-title":"Evaluation of anti-inflammatory impact of dexamethasone-loaded PCL-PEG-PCL micelles on endotoxin-induced uveitis in rabbits","volume":"24","author":"Alami-Milani","year":"2019","journal-title":"Pharm. Dev. Technol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/jop.2014.0152","article-title":"Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application","volume":"31","author":"Patel","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118911_bib80","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1208\/s12249-014-0100-4","article-title":"Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis","volume":"15","author":"Vaishya","year":"2014","journal-title":"Aaps Pharmscitech"},{"issue":"13","key":"10.1016\/j.biopha.2025.118911_bib81","first-page":"5266","article-title":"Topical nanomicelles for the treatment of intermediate and posterior uveitis: focus on micelle size","volume":"55","author":"Natarajan","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2025.118911_bib82","first-page":"1076","article-title":"Novel aqueous nanomicellar formulations containing fluocinolone acetonide for the treatment of posterior uveitis","volume":"54","author":"Shah","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib83","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/10717544.2020.1797241","article-title":"Polymeric micelles for the ocular delivery of triamcinolone acetonide: preparation and in vivo evaluation in a rabbit ocular inflammatory model","volume":"27","author":"Safwat","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2025.118911_bib84","first-page":"2440","article-title":"Development of nano-formulating dexamethasone for anterior uveitis treatment: a randomized clinical trial study","volume":"25","author":"Feghhi","year":"2021","journal-title":"Med Sci."},{"key":"10.1016\/j.biopha.2025.118911_bib85","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jiec.2022.11.072","article-title":"In-situ nanomicelle forming microneedles of poly NIPAAm-b-poly glutamic acid for trans-scleral delivery of dexamethasone","volume":"119","author":"Alimardani","year":"2023","journal-title":"J. Ind. Eng. Chem."},{"issue":"20","key":"10.1016\/j.biopha.2025.118911_bib86","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/nnm-2023-0123","article-title":"Polymeric micelles loaded in situ gel with prednisolone acetate for ocular inflammation: development and evaluation","volume":"18","author":"Kaushal","year":"2023","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/nano9010033","article-title":"In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies","volume":"9","author":"Tatke","year":"2018","journal-title":"Nanomaterials"},{"key":"10.1016\/j.biopha.2025.118911_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118795","article-title":"Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications","volume":"573","author":"Formica","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118911_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.110902","article-title":"Triamcinolone acetonide loaded-cationic nano-lipoidal formulation for uveitis: evidences of improved biopharmaceutical performance and anti-inflammatory activity","volume":"190","author":"Nirbhavane","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib90","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.exer.2005.09.003","article-title":"Treatment of experimental autoimmune uveoretinitis with poly (lactic acid) nanoparticles encapsulating betamethasone phosphate","volume":"82","author":"Sakai","year":"2006","journal-title":"Exp. Eye Res."},{"issue":"16","key":"10.1016\/j.biopha.2025.118911_bib91","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/aafe36","article-title":"Evaluation of controlled-release triamcinolone acetonide-loaded mPEG-PLGA nanoparticles in treating experimental autoimmune uveitis","volume":"30","author":"Guo","year":"2019","journal-title":"Nanotechnology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2008.02.008","article-title":"Dexamethasone acetate encapsulation into Trojan particles","volume":"128","author":"G\u00f3mez-Gaete","year":"2008","journal-title":"J. Control. Release"},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118911_bib93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2018.09.015","article-title":"Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation","volume":"551","author":"Huang","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"13","key":"10.1016\/j.biopha.2025.118911_bib94","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1167\/iovs.12-10743","article-title":"Effects of gold nanoparticles on endotoxin-induced uveitis in rats","volume":"53","author":"Pereira","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2025.118911_bib95","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1167\/iovs.13-12296","article-title":"Improved anti-inflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide","volume":"54","author":"Sabzevari","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib96","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1167\/iovs.10-5676","article-title":"Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis","volume":"52","author":"Sakai","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib97","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/aos.12744","article-title":"Topical dexamethasone\u2013cyclodextrin nanoparticle eye drops for non-infectious uveitic macular oedema and vitritis\u2013a pilot study","volume":"93","author":"Shulman","year":"2015","journal-title":"Acta Ophthalmol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118911_bib98","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3390\/pharmaceutics15092273","article-title":"Topical sustained-release dexamethasone-loaded chitosan nanoparticles: assessment of drug delivery efficiency in a rabbit model of endotoxin-induced uveitis","volume":"15","author":"Alkholief","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib99","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3390\/pharmaceutics15020683","article-title":"Development of triamcinolone acetonide nanocrystals for ocular administration","volume":"15","author":"Formica","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118911_bib100","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.2147\/IJN.S417750","article-title":"Combined therapy of experimental autoimmune uveitis by a dual-drug nanocomposite formulation with berberine and dexamethasone","author":"Huang","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2025.118911_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123006","article-title":"Investigating the effectiveness of difluprednate-loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery","volume":"640","author":"Kaviarasi","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"18","key":"10.1016\/j.biopha.2025.118911_bib102","first-page":"22850","article-title":"Reactive oxygen species-responsive dual anti-inflammatory and antioxidative nanoparticles for anterior uveitis","volume":"16","author":"Zhang","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib103","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/life13041057","article-title":"Cationic nano-lipidic carrier mediated ocular delivery of Triamcinolone acetonide: a preclinical investigation in the management of uveitis","volume":"13","author":"Nirbhavane","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.biopha.2025.118911_bib104","article-title":"Design, optimization and pharmacokinetic evaluation of PLGA phosphatidylcholine hybrid nanoparticles of triamcinolone acetonide loaded in situ gel for topical ocular delivery","volume":"647","author":"Khan","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib105","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ad7e6b","article-title":"Development of chitosan\/sodium carboxymethyl cellulose-based polyelectrolyte complex of dexamethasone for treatment of anterior uveitis","volume":"19","author":"Mujtaba","year":"2024","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.biopha.2025.118911_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.130038","article-title":"Self-assembled sodium alginate polymannuronate nanoparticles for synergistic treatment of ophthalmic infection and inflammation: Preparation optimization and in vitro\/vivo evaluation","volume":"262","author":"Datta","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib107","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/08853282241277345","article-title":"Injectable nanogels to improve triamcinolone acetonide delivery and toxicity on the treatment of eye diseases","volume":"39","author":"Erdal","year":"2025","journal-title":"J. Biomater. Appl."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib108","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/02713683.2023.2298917","article-title":"Fluocinolone acetonide loaded chitosan nanofiber scaffolds for treatment of ocular disorders: in vitro characterization, ex-vivo corneal and ex-vivo scleral evaluation","volume":"49","author":"Patel","year":"2024","journal-title":"Curr. Eye Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib109","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.exer.2007.10.004","article-title":"High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome","volume":"86","author":"Hashida","year":"2008","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2013.01.007","article-title":"Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation","volume":"167","author":"Chennamaneni","year":"2013","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib111","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.msec.2010.10.019","article-title":"Biodegradable polyurethane nanocomposites containing dexamethasone for ocular route","volume":"31","author":"da Silva","year":"2011","journal-title":"Materials science engineering c"},{"key":"10.1016\/j.biopha.2025.118911_bib112","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.colsurfb.2014.09.019","article-title":"Application of electrospraying as a one-step method for the fabrication of triamcinolone acetonide-PLGA nanofibers and nanobeads","volume":"123","author":"Jahangiri","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2025.118911_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113539","article-title":"Design, optimization, in vitro and in vivo evaluation of triamcinolone acetonide nanocrystals loaded in situ gel for topical ocular delivery","volume":"231","author":"Khan","year":"2023","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"10","key":"10.1016\/j.biopha.2025.118911_bib114","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/jop.2017.0053","article-title":"Noninvasive ocular drug delivery system of dexamethasone sodium phosphate in the treatment of experimental uveitis rabbit","volume":"33","author":"Papangkorn","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118911_bib115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.actbio.2017.05.024","article-title":"Calcium ion coordinated dexamethasone supramolecular hydrogel as therapeutic alternative for control of non-infectious uveitis","volume":"61","author":"Wu","year":"2017","journal-title":"Acta Biomater."},{"issue":"23","key":"10.1016\/j.biopha.2025.118911_bib116","doi-asserted-by":"crossref","first-page":"14488","DOI":"10.1039\/C4NR04761C","article-title":"Supramolecular nanofibers of triamcinolone acetonide for uveitis therapy","volume":"6","author":"Li","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2025.118911_bib117","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.actbio.2018.04.019","article-title":"Glycosylation-enhanced biocompatibility of the supramolecular hydrogel of an anti-inflammatory drug for topical suppression of inflammation","volume":"73","author":"Xiong","year":"2018","journal-title":"Acta Biomater."},{"issue":"12","key":"10.1016\/j.biopha.2025.118911_bib118","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.cclet.2021.03.037","article-title":"Bioinspired self-assembly supramolecular hydrogel for ocular drug delivery","volume":"32","author":"Li","year":"2021","journal-title":"Chin. Chem. Lett."},{"issue":"24","key":"10.1016\/j.biopha.2025.118911_bib119","doi-asserted-by":"crossref","first-page":"25377","DOI":"10.1021\/acsnano.3c08869","article-title":"Multifunctional hydrogel eye drops for synergistic treatment of ocular inflammatory disease","volume":"17","author":"Liu","year":"2023","journal-title":"ACS nano"},{"key":"10.1016\/j.biopha.2025.118911_bib120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2015.06.019","article-title":"Polymeric micelles and nanoemulsions as drug carriers: therapeutic efficacy, toxicity, and drug resistance","volume":"212","author":"Gupta","year":"2015","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.biopha.2025.118911_bib121","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/eji.200425022","article-title":"Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis","volume":"34","author":"de Kozak","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biopha.2025.118911_bib122","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11095-013-1184-3","article-title":"In vitro, in vivo, and in silico evaluation of the bioresponsive behavior of an intelligent intraocular implant","volume":"31","author":"Du Toit","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118911_bib123","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11094-018-1870-x","article-title":"Preparation and in vitro\/in vivo evaluation of antihistaminic ocular inserts","volume":"52","author":"Shah","year":"2018","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.biopha.2025.118911_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106631","article-title":"Preparation of polycaprolactone and polymethacrylate nanofibers for controlled ocular delivery of ketorolac tromethamine: pharmacokinetic study in Rabbit's Eye","volume":"192","author":"Taghe","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118911_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112212","article-title":"Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases","volume":"127","author":"Fang","year":"2021","journal-title":"Materials Science Engineering C"},{"key":"10.1016\/j.biopha.2025.118911_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.polymer.2024.127207","article-title":"Latest advances in hydrogel therapy for ocular diseases","volume":"306","author":"Han","year":"2024","journal-title":"Polymer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib127","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nano.2017.09.010","article-title":"Self-assembly of a ibuprofen-peptide conjugate to suppress ocular inflammation","volume":"14","author":"Yu","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2025.118911_bib128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2023.10.030","article-title":"Supramolecular nanofiber of indomethacin derivative confers highly cyclooxygenase-2 (COX-2) selectivity and boosts anti-inflammatory efficacy","volume":"364","author":"Lin","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118911_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121905","article-title":"Chitosan\/sulfobutylether-\u03b2-cyclodextrin based nanoparticles coated with thiolated hyaluronic acid for indomethacin ophthalmic delivery","volume":"622","author":"Ricci","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib130","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1089\/jop.2016.0167","article-title":"A prostacyclin analog, cicaprost, exhibits potent anti-inflammatory activity in human primary immune cells and a uveitis model","volume":"33","author":"Wang","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118911_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124178","article-title":"Subconjunctival injection of rapamycin-loaded polymeric microparticles for effective suppression of noninfectious uveitis in rats","volume":"657","author":"Mo","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118911_bib132","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1208\/s12249-014-0244-2","article-title":"Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery","volume":"16","author":"Cholkar","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118911_bib133","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijpharm.2016.09.013","article-title":"Intravitreal injection of rapamycin-loaded polymeric micelles for inhibition of ocular inflammation in rat model","volume":"513","author":"Wu","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118911_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121755","article-title":"The topical ocular delivery of rapamycin to posterior eye tissues and the suppression of retinal inflammatory disease","volume":"621","author":"Badr","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118911_bib135","article-title":"Therapeutic effect of rapamycin-loaded small extracellular vesicles derived from mesenchymal stem cells on experimental autoimmune uveitis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib136","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","article-title":"Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly (ethylene glycol)-hexylsubstituted poly (lactide) micelle carriers","volume":"416","author":"Di Tommaso","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2025.118911_bib137","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1021\/acs.molpharmaceut.8b00014","article-title":"Cyclosporine a-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis","volume":"15","author":"Kasper","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118911_bib138","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.exer.2018.01.003","article-title":"Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU)","volume":"168","author":"Kasper","year":"2018","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2025.118911_bib139","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2017.08.007","article-title":"Incorporation of drug particles for extended release of Cyclosporine A from poly-hydroxyethyl methacrylate hydrogels","volume":"120","author":"Kapoor","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.biopha.2025.118911_bib140","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/pharmaceutics13081227","article-title":"Pharmacokinetics and toxicity evaluation of a PLGA and chitosan-based micro-implant for sustained release of methotrexate in rabbit vitreous","volume":"13","author":"Manna","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib141","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.mehy.2013.08.007","article-title":"Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis","volume":"81","author":"Garg","year":"2013","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.biopha.2025.118911_bib142","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.colsurfb.2017.05.049","article-title":"Proglycosomes: a novel nano-vesicle for ocular delivery of tacrolimus","volume":"157","author":"Garg","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib143","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.xphs.2020.10.060","article-title":"Amelioration of endotoxin-induced uveitis in rabbit by topical administration of tacrolimus proglycosome nano-vesicles","volume":"110","author":"Garg","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118911_bib144","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jconrel.2021.03.035","article-title":"Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models","volume":"333","author":"Rebibo","year":"2021","journal-title":"J. Control. Release"},{"issue":"13","key":"10.1016\/j.biopha.2025.118911_bib145","first-page":"428","article-title":"Nanogel for delivering Fk506 across ocular biological barriers to treat uveitis","volume":"51","author":"Zhang","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2025.118911_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117216","article-title":"Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment","volume":"253","author":"Chen","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2025.118911_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105735","article-title":"A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study","volume":"159","author":"Mehra","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118911_bib148","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jconrel.2024.06.047","article-title":"Polyvinylpyrrolidone-curcumin nanoparticles with immune regulatory and metabolism regulatory effects for the treatment of experimental autoimmune uveitis","volume":"372","author":"Cao","year":"2024","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib149","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1021\/acs.molpharmaceut.6b01066","article-title":"Potential eye drop based on a calix [4] arene nanoassembly for curcumin delivery: enhanced drug solubility, stability, and anti-inflammatory effect","volume":"14","author":"Granata","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118911_bib150","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1007\/s12274-018-1994-z","article-title":"Enzymatic formation of curcumin in vitro and in vivo","volume":"11","author":"Wang","year":"2018","journal-title":"Nano Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib151","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s40824-023-00451-1","article-title":"Fe-curcumin nanozyme-mediated immunosuppression and anti-inflammation in experimental autoimmune uveitis","volume":"27","author":"Jiang","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.biopha.2025.118911_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122617","article-title":"Multifunctional nanogel loaded with cerium oxide nanozyme and CX3CL1 protein: targeted immunomodulation and retinal protection in uveitis rat model","volume":"309","author":"Jin","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2025.118911_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122068","article-title":"Spanlastic nanovesicles for enhanced ocular delivery of vanillic acid: Design, in vitro characterization, and in vivo anti-inflammatory evaluation","volume":"625","author":"Ibrahim","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib154","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/jfb14040197","article-title":"Lutein encapsulated in PLGA\u2013phospholipid nano-carrier effectively mitigates cytokines by inhibiting tumor necrosis factor TNF-\u03b1 and nuclear factor NF-\u03ba B in mice retina","volume":"14","author":"Arunkumar","year":"2023","journal-title":"J. Funct. Biomater."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0939-6411(97)00064-7","article-title":"Ocular pharmacokinetics\/pharmacodynamics","volume":"44","author":"Worakul","year":"1997","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib156","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib157","doi-asserted-by":"crossref","first-page":"57","DOI":"10.15212\/bioi-2021-0016","article-title":"Challenges and opportunities of nanomedicines in clinical translation","volume":"2","author":"Zheng","year":"2021","journal-title":"Bio Integr."},{"issue":"7","key":"10.1016\/j.biopha.2025.118911_bib158","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.nano.2016.05.017","article-title":"Physicochemical properties of core\u2013shell type nanoparticles govern their spatiotemporal biodistribution in the eye","volume":"12","author":"Mahaling","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib159","article-title":"Scale-up and quality control challenges in the industrial manufacturing of nanoformulations: current trends and future perspectives","volume":"16","author":"Sammasagi","year":"2025","journal-title":"IJSATInt. J. Sci. Technol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib160","article-title":"Challenges and opportunities in the industrial scale-up of nanoparticle-based drug delivery systems","volume":"7","author":"Kumar","year":"2025","journal-title":"J. Res. Pharm. Ind. Pharm."},{"issue":"35","key":"10.1016\/j.biopha.2025.118911_bib161","doi-asserted-by":"crossref","first-page":"16485","DOI":"10.1039\/C8NR00058A","article-title":"A non-invasive nanoparticle mediated delivery of triamcinolone acetonide ameliorates diabetic retinopathy in rats","volume":"10","author":"Mahaling","year":"2018","journal-title":"Nanoscale"},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/jnt5040010","article-title":"Drug delivery systems for infectious eye diseases: advancements and prospects","volume":"5","author":"Mahaling","year":"2024","journal-title":"J. Nanotheranostics"},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib163","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine scale-up technologies: feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib164","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1021\/acs.biomac.0c00726","article-title":"Exploring the impact of morphology on the properties of biodegradable nanoparticles and their diffusion in complex biological medium","volume":"22","author":"Ridolfo","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biopha.2025.118911_bib165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib166","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"20","key":"10.1016\/j.biopha.2025.118911_bib167","doi-asserted-by":"crossref","first-page":"15352","DOI":"10.3390\/ijms242015352","article-title":"Overview of recent advances in nano-based ocular drug delivery","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118911_bib168","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jconrel.2021.05.035","article-title":"Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration","volume":"335","author":"Kambhampati","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118911_bib169","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2015.02.019","article-title":"Nanotherapies for the treatment of ocular diseases","volume":"95","author":"Reimondez-Troiti\u00f1o","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2025.118911_bib170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.pmbts.2024.08.003","article-title":"Delivery of therapeutic proteins to ocular tissues: barriers, approaches, regulatory considerations and future perspectives","volume":"212","author":"Shastri","year":"2025","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"02","key":"10.1016\/j.biopha.2025.118911_bib171","article-title":"Nanocarrier-based formulations: regulatory challenges, ethical and safety considerations in pharmaceuticals","volume":"18","author":"Kardani","year":"2024","journal-title":"Asian J. Pharm. (AJP)"},{"key":"10.1016\/j.biopha.2025.118911_bib172","series-title":"Commercial Scale Production of Nanomedicines","first-page":"1","article-title":"Challenges for commercial translation of nanomedicines: From lab scale to production scale","author":"Khopade","year":"2025"},{"key":"10.1016\/j.biopha.2025.118911_bib173","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle therapeutics in clinical perspective: classification, marketed products, and regulatory landscape","author":"Desai","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.biopha.2025.118911_bib174","series-title":"Pharmaceutical regulation of nanomedicines: Principles and challenges","author":"Lousa","year":"2024"},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bcp.14130","article-title":"Food and drug administration vs european medicines agency: review times and clinical evidence on novel drugs at the time of approval","volume":"86","author":"Joppi","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118911_bib176","first-page":"742","article-title":"Progress in nanomedicine: approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"Pharm. Ther."},{"issue":"17","key":"10.1016\/j.biopha.2025.118911_bib177","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1039\/D0BM00558D","article-title":"The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives","volume":"8","author":"Foulkes","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biopha.2025.118911_bib178","first-page":"150","article-title":"Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration","volume":"14","author":"Amrite","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.biopha.2025.118911_bib179","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog. Retin. eye Res."},{"key":"10.1016\/j.biopha.2025.118911_bib180","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2023.01.018","article-title":"Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases","volume":"354","author":"Onugwu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118911_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2024.103200","article-title":"Intravitreal therapeutic nanoparticles for age-related macular degeneration: design principles, progress and opportunities","volume":"329","author":"Zhang","year":"2024","journal-title":"Adv. Colloid Interface Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib182","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/pharmaceutics15030734","article-title":"Updates on biodegradable formulations for ocular drug delivery","volume":"15","author":"Tsung","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118911_bib183","series-title":"Complex Ophthalmic Dosage Forms: Advances in Biomedical Applications and Future Perspectives","first-page":"307","article-title":"Safety and toxicities of nanocarriers in ophthalmic drug delivery system","author":"Kadiri","year":"2025"},{"key":"10.1016\/j.biopha.2025.118911_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114911","article-title":"A state of the art in analytical quality-by-design and perspectives in characterization of nano-enabled medicinal products","volume":"219","author":"Bastogne","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib185","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.drudis.2018.01.047","article-title":"Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities","volume":"23","author":"Agrahari","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib186","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s40123-023-00827-5","article-title":"Allogeneic serum eye drops: a randomized clinical trial to evaluate the clinical effectiveness of two drop sizes","volume":"12","author":"Vermeulen","year":"2023","journal-title":"Ophthalmol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118911_bib187","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bjo.87.4.436","article-title":"A comparative bioavailability study of three conventional eye drops versus a single lyophilisate","volume":"87","author":"Lux","year":"2003","journal-title":"Br. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118911_bib188","first-page":"651","article-title":"The efficacy evaluation study of the clinical eye drop formulation of the NOX inhibitor, SJP1804 and the design of a phase 1 clinical trial for the treatment of wet AMD","volume":"62","author":"Back","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib189","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Arch. Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/OPTH.S2561","article-title":"Potential bias in ophthalmic pharmaceutical clinical trials","volume":"2","author":"Varner","year":"2008","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118911_bib191","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2147\/TCRM.S331294","article-title":"Reexamining ophthalmic drugs, safety and tolerability in phase 1 clinical trials","author":"Mu\u00f1oz-Villegas","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"issue":"9","key":"10.1016\/j.biopha.2025.118911_bib192","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3928\/23258160-20170829-08","article-title":"Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema","volume":"48","author":"Neto","year":"2017","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib193","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/09286586.2022.2131837","article-title":"A systematic review of clinical trials in uveitis: lessons learned","volume":"30","author":"Lobo-Chan","year":"2023","journal-title":"Ophthalmic Epidemiol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118911_bib194","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000517521","article-title":"Structural endpoints and outcome measures in uveitis","volume":"244","author":"Wintergerst","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.biopha.2025.118911_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.610428","article-title":"Protein biomarkers in uveitis","volume":"11","author":"Bansal","year":"2020","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.biopha.2025.118911_bib196","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.3390\/jcm11237034","article-title":"Tear and plasma levels of cytokines in patients with uveitis: search for active disease biomarkers","volume":"11","author":"Garc\u00eda-Onrubia","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib197","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/pharmaceutics15030766","article-title":"Perspectives of therapeutic drug monitoring of biological agents in non-infectious uveitis treatment: a review","volume":"15","author":"Busto-Iglesias","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biopha.2025.118911_bib198","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/pharmaceutics15061583","article-title":"Exploring the potential of nanotechnology in pediatric healthcare: advances, challenges, and future directions","volume":"15","author":"Omidian","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118911_bib199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2016.01.053","article-title":"Understanding the influence of surface properties of nanoparticles and penetration enhancers for improving bioavailability in eye tissues in vivo","volume":"501","author":"Mahaling","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2025.118911_bib200","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3390\/biomedicines11071901","article-title":"The evolution of triamcinolone acetonide therapeutic use in retinal diseases: from off-label intravitreal injection to advanced nano-drug delivery systems","volume":"11","author":"Aceves-Franco","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118911_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2023.102848","article-title":"Amphotericin B loaded nanoemulsion: optimization, characterization and in-vitro activity against L. donovani promastigotes","volume":"100","author":"Prajapat","year":"2024","journal-title":"Parasitol. Int."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib202","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2476140","article-title":"External stimuli-responsive drug delivery to the posterior segment of the eye","volume":"32","author":"Xu","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2025.118911_bib203","series-title":"Stimuli-Responsive Hydrogels for Ophthalmic Drug Delivery","author":"Chattopadhyay","year":"2024"},{"issue":"24","key":"10.1016\/j.biopha.2025.118911_bib204","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13247651","article-title":"Nanomedicine in ophthalmology: from bench to bedside","volume":"13","author":"Mahaling","year":"2024","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2025.118911_bib205","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.931759","article-title":"Nanoparticles in ocular applications and their potential toxicity","volume":"9","author":"Yang","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biopha.2025.118911_bib206","series-title":"Nanomedicine: Innovations, Applications, and Breakthroughs in the Quest for Health and Medicine's Future","first-page":"15","article-title":"Navigating safety and toxicity challenges in nanomedicine: Strategies, assessment, and mitigation","author":"Kumar","year":"2024"},{"issue":"45","key":"10.1016\/j.biopha.2025.118911_bib207","article-title":"A safe-by-design strategy towards safer nanomaterials in nanomedicines","volume":"31","author":"Yan","year":"2019","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-025-04234-6","article-title":"Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases","volume":"20","author":"Bairagi","year":"2025","journal-title":"Discov. Nano"},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib209","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/gels8020082","article-title":"Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system","volume":"8","author":"Akhter","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.biopha.2025.118911_bib210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2024.04.026","article-title":"Intraocular immune response in human uveitis: time to look beyond animal models","volume":"266","author":"Basu","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118911_bib211","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.2147\/IJN.S532074","article-title":"Nanomedicine-based ophthalmic drug delivery systems for the treatment of ocular diseases","author":"Lin","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.biopha.2025.118911_bib212","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.drudis.2019.05.005","article-title":"Intravitreal nanoparticles for retinal delivery","volume":"24","author":"Huang","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib213","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02713683.2022.2119254","article-title":"Vitreous humor: composition, characteristics and implication on intravitreal drug delivery","volume":"48","author":"Mishra","year":"2023","journal-title":"Curr. eye Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118911_bib214","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40005-018-0404-6","article-title":"Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations","volume":"49","author":"Maharjan","year":"2019","journal-title":"J. Pharm. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2025.118911_bib215","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90792-5","article-title":"Stability and ocular biodistribution of topically administered PLGA nanoparticles","volume":"11","author":"Swetledge","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118911_bib216","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/ph16030474","article-title":"Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms","volume":"16","author":"Gugleva","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225011059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225011059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:34:54Z","timestamp":1769034894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225011059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":216,"alternative-id":["S0753332225011059"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118911","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing uveitis treatment with nanotechnology: Innovations, barriers, and strategic solutions","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118911"}}